Abstract
One of the major obstacles in the development of bispecific antibodies (BsAb) has been the difficulty of producing the materials in sufficient quality and quantity by traditional technologies, such as the hybrid hybridoma and chemical conjugation methods. In contrast to the rapid and significant progress in the development of recombinant BsAb fragments (such as diabody and tandem single chain Fv), the successful design and production of full length IgG-like BsAb has been limited. Compared to smaller fragments, IgG-like BsAb have long serum half-life and are capable of supporting secondary immune functions, such as antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. The development of IgG-like BsAb as therapeutic agents will depend heavily on our research progress in the design of recombinant BsAb constructs (or formats) and production efficiency. This review will focus on recent advances in various recombinant approaches to the engineering and production of IgG-like BsAb.
Similar content being viewed by others
Article PDF
References
Sidhu SS . Phage display in biotechnology and drug discovery. New York (NY): Marcel Dekker; 2005.
Colby DW, Kellogg BA, Graff CP, Yeung YA, Swers JS, Wittrup KD . Engineering antibody affinity by yeast surface display. Methods Enzymol 2004; 388: 348–58.
Lipovsek D, Pluckthun A . In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 2004; 290: 51–67.
Ferrara N, Hillan KJ, Gerber HP, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391–400.
Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443–53.
Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, Iverson BL, et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002; 20: 597–601.
Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002; 99: 11346–50.
Li S, Schmitz K, Jeffery PD, Wiltzius J, Kussie P, Ferguson KM . Structural basis for inhibition of the epidermal growth factor receptor by cetuximab/Erbitux. Cancer Cell 2005; in press:.
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX . Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317–28.
Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954–60.
Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K . TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95: 777–83.
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–48.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 2001; 344: 783–92.
Clynes RA, Towers TL, Presta LG, Ravetch JV . Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443–6.
Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL . Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev 2004; 30: 165–72.
Xiong D, Xu Y, Liu H, Peng H, Shao X, Lai Z, et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20×anti-CD3 bispecific diabody. Cancer Lett 2002; 177: 29–39.
Kipriyanov SM, Cochlovius B, Schafer HJ, Moldenhauer G, Bahre A, Le Gall F, et al. Synergistic antitumor effect of bispecific CD19×CD3 and CD19×CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 2002; 169: 137–44.
James ND, Atherton PJ, Jones J, Howie AJ, Tchekmedyian S, Curnow RT . A phase II study of the bispecific antibody MDX-H210 (anti-HER2×CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer 2001; 85: 152–6.
Baeuerle PA, Kufer P, Lutterbuse R . Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther 2003; 5: 413–9.
Cao Y, Lam L . Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 2003; 55: 171–97.
Corvalan JR, Smith W, Gore VA . Tumour therapy with Vinca alkaloids targeted by a hybrid-hybrid monoclonal antibody recognising both CEA and Vinca alkaloids. Int J Cancer Suppl 1988; 2: 22–5.
Ford CH, Osborne PA, Rego BG, Mathew A . Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo. Int J Cancer 2001; 92: 851–5.
Ferrini S, Sforzini S, Canevari S . Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies. Methods Mol Biol 2001; 166: 177–92.
Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, et al. Molecular advances in pretargeting radio-imunotherapy with bispecific antibodies. Mol Cancer Ther 2002; 1: 553–63.
Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 2001; 61: 7002–8.
Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; March 9 [Epub ahead of print].
Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279: 2856–65.
Milstein C, Cuello AC . Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305: 537–40.
Brennan M, Davison PF, Paulus H . Preparation of biospecific antibodies by chemical recombination of monoclonal immuno-globulin G1 fragments. Science 1985; 229: 81–3.
Carter P, Ridgway J, Zhu Z . Toward the production of bispecific antibody fragments for clinical applications. J Hematother 1995; 4: 463–70.
Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ . Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001; 248: 47–66.
Kontermann RE . Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005; 26: 1–9.
Ridgway JB, Presta LG, Carter P . ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9: 617–21.
Deisenhofer J . Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9– and 2.8-A resolution. Biochemistry 1981; 20: 2361–70.
Atwell S, Ridgway JB, Wells JA, Carter P . Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270: 26–35.
Zhu Z, Presta LG, Zapata G, Carter P . Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6: 781–8.
Eigenbrot C, Randal M, Presta L, Carter P, Kossiakoff AA . X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol 1993; 229: 969–95.
Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16: 677–81.
Xie Z, Guo N, Yu M, Hu M, Shen B . A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 2005; 296: 95–101.
Coloma MJ, Trinh KR, Wims LA, Morrison SL . The hinge as a spacer contributes to covalent assembly and is required for function of IgG. J Immunol 1997; 158: 733–40.
Zuo Z, Jimenez X, Witte L, Zhu Z . An efficient route to the production of an IgG-like bispecific antibody. Protein Eng 2000; 13: 361–7.
Holliger P, Prospero T, Winter G . “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444–8.
Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P . High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology (NY) 1996; 14: 192–6.
Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191–7.
Kipriyanov SM . Generation of bispecific and tandem diabodies. Methods Mol Biol 2002; 178: 317–31.
Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmcokinetics. J Mol Biol 1999; 293: 41–56.
Alt M, Muller R, Kontermann RE . Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 1999; 454: 90–4.
Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, et al. Didiabody: a novel tetravalent bispecific antibody molecule by design. J Immunol Methods 2003; 279: 219–32.
Jung SH, Pastan I, Lee B . Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins 1994; 19: 35–47.
FitzGerald K, Holliger P, Winter G . Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 1997; 10: 1221–5.
Worn A, Pluckthun A . Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001; 305: 989–1010.
Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R . Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 1994; 7: 1129–35.
Riechmann L, Muyldermans S . Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods 1999; 231: 25–38.
Els Conrath K, Lauwereys M, Wyns L, Muyldermans S . Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001; 276: 7346–50.
Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, et al. Design, construction, and in vitro analyses of multivalent antibodies. J Immunol 2003; 170: 4854–61.
Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, et al. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 1999; 230: 159–71.
Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z . Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J Immunol Methods 2002; 267: 213–26.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marvin, J., Zhu, Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26, 649–658 (2005). https://doi.org/10.1111/j.1745-7254.2005.00119.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00119.x
Keywords
This article is cited by
-
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Journal of Experimental & Clinical Cancer Research (2019)
-
Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance
Scientific Reports (2018)
-
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
Scientific Reports (2017)
-
Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification
Experimental & Molecular Medicine (2013)
-
Therapeutic antibodies for autoimmunity and inflammation
Nature Reviews Immunology (2010)